Form 4: Tharimmune CEO Granted Stock Options

Tharimmune CEO Randy Milby was granted options to purchase 80,958 shares of common stock on January 13, 2025.

Summary

• Tharimmune CEO Randy Milby was granted options to purchase 80,958 shares of the company's common stock.
• The options were granted on January 13, 2025, with an exercise price of $1.93 per share.
• These options vest immediately upon grant and expire on January 13, 2035.
• Following this transaction, Mr. Milby directly owns 138,665 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to slightly positive. The immediate vesting is a positive for the executive.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The immediate vesting of the options could incentivize the CEO to focus on short-term performance.

Risks

• The exercise of these options could potentially dilute existing shareholders' ownership.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of immediate vesting is less common than a phased vesting schedule, but not unheard of.
• The exercise price of $1.93 is a specific value related to the company's stock price at the time of the grant.

Stakeholder Impact

• Shareholders may experience potential dilution if the options are exercised.
• The grant of options may incentivize the CEO to focus on increasing shareholder value.

Key Dates

Keywords

stock options, executive compensation, insider trading, equity incentive, Tharimmune, CEO, Randy Milby